CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 69 enrolled
Drug / intervention
Pemetrexed +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01087970
NCT01087970Phase 2Completed
CompareCT.gov

Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Eli Lilly and Company·interventional·Posted Mar 16, 2010·Updated May 19, 2014

In Brief

A Phase 2 clinical trial evaluating Pemetrexed, Cetuximab, and 2 other interventions for Head and Neck Neoplasms. Completed, enrolled 69 participants across 21 sites.

Detailed Summary

The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell carcinoma of the head and neck.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Neoplasms
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 16, 2010
Enrollment StartAug 1, 2010
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 16.3 years ago

Interventions

Pemetrexeddrug

Administered intravenously, for maximum of 6 cycles.

Cetuximabdrug

Administered intravenously in combination therapy, for a maximum of 6 cycles. After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression.

Carboplatindrug

Administered intravenously, for a maximum of 6 cycles

Cisplatindrug

Administered intravenously, for a maximum of 6 cycles